The World Health Organization (WHO) and the Joint United Nations Programme on
HIV/AIDS (UNAIDS) today welcomed the G8's endorsement of the Global HIV
Vaccine Enterprise, a virtual consortium proposed by an international group of scientists that is being established to accelerate HIV vaccine development.
HIV/AIDS vaccine development has been slow, due mainly to the enormous scientific, logistical and financial challenges involved. Since the discovery of the human immunodeficiency virus (HIV) as the cause of AIDS in 1983/84, multiple vaccine candidates have been tested in more than 70 human clinical trials with moderate success. So far, only one vaccine candidate has concluded the stage of definitive trials and it did not show any noticeable level of efficacy. This indicates a need to consolidate and intensify all international efforts to ensure further progress in this field.
"I welcome the G8's endorsement of this initiative. The Global HIV Vaccine Enterprise will bring a new political and financial dimension to addressing the complex challenge of developing a safe and effective HIV/AIDS vaccine," said Dr LEE Jong-wook, Director-General of WHO.
The Global HIV Vaccine Enterprise would enhance coordination, information sharing and global collaboration amongst the world's HIV vaccine researchers in industrialized and developing countries in both private and public sectors. It would prioritize the scientific challenges that need to be addressed, coordinate product development efforts and encourage greater use of information sharing technologies. Existing resources would be better aligned and would be channeled more efficiently. Its work would also promote more effective synergies between research into new technologies and global efforts to scale up the preventive and therapeutic interventions for HIV/AIDS which already exist.